SCHEMBL2676202

SCHEMBL2676202

CCOC(=O)CCCCC(Cc1cc(F)c(O[Si](C(C)C)(C(C)C)C(C)C)c(F)c1)C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PTGES O14684 3/20 0.35
ALOX5 P09917 3/20 0.35
PPARG P37231 3/20 0.35
PPARA Q07869 2/20 0.34
PPARD Q03181 1/20 0.34
CYP1A2 P05177 1/20 0.33
KMT2A Q03164 2/20 0.33
TNF P01375 1/20 0.32
FOLH1 Q04609 3/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP4F2 P78329 1/20 0.32
CYP4A11 Q02928 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4547668 0.86 ALOX5 (0.40) PTGESALOX5PPARGPPARACYP1A2
SCHEMBL2675358 0.86 CYP4F2 (0.33) CYP1A2KMT2ATNFALDH1A1CYP4F2
SCHEMBL2675514 0.85 CYP1A2 (0.32) CYP1A2KMT2ATNFALDH1A1CYP4F2
SCHEMBL4550996 0.84 ALOX5 (0.39) PTGESALOX5PPARGPPARACYP1A2
SCHEMBL2674943 0.72 FOLH1 (0.42) PPARGPPARAPPARDCYP1A2FOLH1
SCHEMBL9442220 0.71 FOLH1 (0.48) PTGESALOX5PPARGPPARACYP1A2
SCHEMBL4547657 0.70 CYP1A2 (0.40) CYP1A2KMT2ATNFALDH1A1CYP4F2
SCHEMBL2295351 0.70 FOLH1 (0.46) PTGESALOX5PPARGPPARAFOLH1
SCHEMBL4547658 0.69 CYP1A2 (0.39) CYP1A2KMT2ATNFALDH1A1CYP4F2
SCHEMBL4603333 0.68 TSHR (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940808-B1 DIFLUOROPHENOL DERIVATIVES AND THEIR USE BAYER IP GMBH (DE) 2013-11-27 EP disclosed
US-8173704-B2 Difluorophenol derivatives and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-05-08 US disclosed
US-8173704-B2 Difluorophenol derivatives and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-05-08 US disclosed
US-20090291993-A1 Difluorophenol Derivatives and Their Use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-11-26 US disclosed
US-20090291993-A1 Difluorophenol Derivatives and Their Use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-11-26 US disclosed
EP-1940808-A1 DIFLUOROPHENOL DERIVATIVES AND THEIR USE Bayer HealthCare AG (DE) 2008-07-09 EP disclosed
WO-2007045369-A1 DIFLUOROPHENOL DERIVATIVES AND THEIR USE BAYER HEALTHCARE AG (DE) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291993-A1 Difluorophenol Derivatives and Their Use TPMT, FABP3, DPP4 PTGES 1662/4885ALOX5 1580/4885PPARG 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.